PharmacyCodes



Mirtazapina [Inn-Spanish] en es it fr

Mirtazapina [Inn-Spanish] Brand names, Mirtazapina [Inn-Spanish] Analogs

Mirtazapina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Mirtazapina [Inn-Spanish] Chemical_Formula

C17H19N3

Mirtazapina [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/mirtaz.htm

Mirtazapina [Inn-Spanish] fda sheet

Mirtazapina_[Inn-Spanish] FDA

Mirtazapina [Inn-Spanish] msds (material safety sheet)

Mirtazapina_[Inn-Spanish] MSDS

Mirtazapina [Inn-Spanish] Synthesis Reference

W. J. Van der Burg, U.S. Pat. 4,062,848 (1977)

Mirtazapina [Inn-Spanish] Molecular Weight

265.353 g/mol

Mirtazapina [Inn-Spanish] Melting Point

114-116oC

Mirtazapina [Inn-Spanish] H2O Solubility

Slight

Mirtazapina [Inn-Spanish] State

Solid

Mirtazapina [Inn-Spanish] LogP

2.369

Mirtazapina [Inn-Spanish] Dosage Forms

Tablet; Tablet (orally disintegrating)

Mirtazapina [Inn-Spanish] Indication

For the treatment of major depressive disorder.

Mirtazapina [Inn-Spanish] Pharmacology

Mirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.

Mirtazapina [Inn-Spanish] Absorption

Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.

Mirtazapina [Inn-Spanish] side effects and Toxicity

Symptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50=mg/kg (orally in rat).

Mirtazapina [Inn-Spanish] Patient Information

Mirtazapina [Inn-Spanish] Organisms Affected

Humans and other mammals